Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal
AuthID
P-00Q-9Y0
P-00Q-9Y0
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service